What is the official website of Lilly Gastroenterology ?

The official website of Lilly Gastroenterology is https://e.lilly/4bSHvqm.

What is Lilly Gastroenterology's cybersecurity risk score?

Lilly Gastroenterology has an AI-generated cybersecurity risk score of 753 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Lilly Gastroenterology experienced?

According to Rankiteo, Lilly Gastroenterology currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Lilly Gastroenterology been affected by any supply chain cyber incidents ?

According to Rankiteo, Lilly Gastroenterology has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Lilly Gastroenterology have SOC 2 Type 1 certification ?

According to Rankiteo, Lilly Gastroenterology is not certified under SOC 2 Type 1.

Does Lilly Gastroenterology have SOC 2 Type 2 certification ?

According to Rankiteo, Lilly Gastroenterology does not hold a SOC 2 Type 2 certification.

Does Lilly Gastroenterology comply with GDPR ?

According to Rankiteo, Lilly Gastroenterology is not listed as GDPR compliant.

Does Lilly Gastroenterology have PCI DSS certification ?

According to Rankiteo, Lilly Gastroenterology does not currently maintain PCI DSS compliance.

Does Lilly Gastroenterology comply with HIPAA ?

According to Rankiteo, Lilly Gastroenterology is not compliant with HIPAA regulations.

Does Lilly Gastroenterology have ISO 27001 certification ?

According to Rankiteo,Lilly Gastroenterology is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Lilly Gastroenterology operate in ?

Lilly Gastroenterology operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Lilly Gastroenterology have ?

Lilly Gastroenterology employs approximately None employees people worldwide.

Does Lilly Gastroenterology own any subsidiaries ?

Lilly Gastroenterology presently has no subsidiaries across any sectors.

How many LinkedIn followers does Lilly Gastroenterology have ?

Lilly Gastroenterology's official LinkedIn profile has approximately 1,751 followers.

What is the NAICS classification code for Lilly Gastroenterology ?

Lilly Gastroenterology is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Lilly Gastroenterology have a Crunchbase profile ?

No, Lilly Gastroenterology does not have a profile on Crunchbase.

Does Lilly Gastroenterology have a LinkedIn profile ?

Yes, Lilly Gastroenterology maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/lilly-gastroenterology-eu.

How many cybersecurity incidents has Lilly Gastroenterology experienced ?

As of August 29, 2026, Rankiteo reports that Lilly Gastroenterology has not experienced any cybersecurity incidents.

How many peer or competitor companies does Lilly Gastroenterology have ?

Lilly Gastroenterology has an estimated 5,746 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Lilly Gastroenterology

Boost Score +25 with badge (5 left)

753

/1000

Fair

778

/1000

Fair

Lilly Gastroenterology Vendor Cyber Rating & Cyber Score

e.lilly

Add Your Compliance Badge

Lilly unites caring with discovery to make life better for people around the world. When you engage with Lilly on LinkedIn (and any other of Lilly’s social media channels), you are agreeing to these Community Guidelines in addition to the Terms and Conditions or other legal notices provided by Lilly and those of LinkedIn.

Lilly Gastroenterology A.I CyberSecurity Scoring

Scoring History

Lilly Gastroenterology

Lilly Gastroenterology CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Lilly Gastroenterology Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Lilly Gastroenterology

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Lilly Gastroenterology in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Lilly Gastroenterology in 2026.

Incident Types Lilly Gastroenterology vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Lilly Gastroenterology in 2026.

Incident History - Lilly Gastroenterology (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Lilly Gastroenterology Subsidiaries

Lilly Gastroenterology

Pharmaceutical Manufacturing

Website: https://e.lilly/4bSHvqm

Company Size: 10,001+ employees

Eli Lilly and CompanyPharmaceutical Manufacturing

Eli Lilly ItaliaFabbricazione di prodotti farmaceutici

Lilly LatamFabricación de productos farmacéuticos

Lilly EspañaFabricación de productos farmacéuticos

Lilly IndiaPharmaceutical Manufacturing

Loading…

Lilly Gastroenterology Similar Companies

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

Cipla

cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

MSD

msd.com

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.

Viatris

viatris.com

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

Ipca Laboratories Limited

ipca.com

A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high qualiti standards become a pre-requisite, and safeti of your people and consumers always comes first. All this, while ensuring that each life you touch is treated with respect and digniti. For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others. - One of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally - 15 APIs & 11 Formulations manufacturing facility across the globe Leader in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for Rheumatoid Arthritis - Leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy - 4 formulations rank amongst the top 300 brands of IPM as per IQVIA

Lupin

lupin.com

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

Parexel

parexel.com

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Intas Pharmaceuticals

intaspharma.com

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

Loading…

NEWS

Lilly Gastroenterology CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

January 15, 2025 08:00 AM

US FDA approves expanded use of Lilly's bowel disease drug

Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's disease,...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-55867

SUMMARY

Graylog is a free and open log management platform. From 6.2.0 until 6.3.12, 7.0.7, and 7.1.2, the DELETE /users/{userId}/tokens/{idOrToken} endpoint implemented by UsersResource.revokeToken() in graylog2-server/src/main/java/org/graylog2/rest/resources/users/UsersResource.java checks USERS_TOKENREMOVE permission against the attacker-controlled userId path parameter before resolving the token selected by idOrToken. An authenticated user can provide an authorized userId while accessTokenService.loadById() or accessTokenService.load() resolves a token belonging to another user, including a service account or administrator, after which accessTokenService.destroy() deletes that token without checking AccessToken.getUserName(). The issue does not expose token contents, but unauthorized deletion causes integrity impact and can disrupt access-token-based integrations. This issue is fixed in versions 6.3.12, 7.0.7, and 7.1.2.

Published

Date2026-08-28

Updated

Date2026-08-28

RISK INFORMATION (Score: )

cvss4

Base Score: 5.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:N/VI:L/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-55860

SUMMARY

MariaDB Connector/R2DBC is a non-blocking MariaDB and MySQL client implemented in Java. Prior to 1.4.1, org.mariadb:r2dbc-mariadb does not gate clear-text password authentication plugins on transport encryption because the AuthenticationPlugin interface has no capability for a plugin to require a secure connection. A hostile or man-in-the-middle MariaDB server can send an AuthSwitchRequest naming mysql_clear_password or dialog (PAM) over a plain-TCP unencrypted connection, and AuthenticationFlow permits ClearPasswordPluginFlow or PamPluginFlow to return the user's password as cleartext bytes on the wire. The disclosed credentials can subsequently be used to authenticate directly to the database server. This issue is fixed in version 1.4.1.

Published

Date2026-08-28

Updated

Date2026-08-28

RISK INFORMATION (Score: 5.9)

cvss3

Base Score: 5.9

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:H/I:N/A:N

Impact Score

3.6

Exploitability

2.2

REFERENCES

CVE-2026-55859

SUMMARY

MariaDB Connector/R2DBC is a non-blocking MariaDB and MySQL client implemented in Java. Prior to 1.4.1, org.mariadb:r2dbc-mariadb encodes and decodes all character data under the assumption that the connection character set is UTF-8. A server can announce a mid-session change to character_set_client through the OK-packet session-state-tracking mechanism, including through SET NAMES executed by a stored routine or trigger, server configuration, or a hostile or man-in-the-middle server. If the new character set is not UTF-8, the driver continues to exchange UTF-8 while the server interprets the same bytes under a different encoding, causing silent data corruption and a client/server charset-confusion mismatch that can defeat byte-wise quoting or escaping. The fix accepts only utf8, utf8mb3, or utf8mb4 after initialization; any other value raises R2dbcNonTransientResourceException with SQLState 08000 and closes the connection. This issue is fixed in version 1.4.1.

Published

Date2026-08-28

Updated

Date2026-08-28

RISK INFORMATION (Score: 5.9)

cvss3

Base Score: 5.9

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:H/A:N

Impact Score

3.6

Exploitability

2.2

REFERENCES

CVE-2026-55858

SUMMARY

MariaDB Connector/J is used to connect applications developed in Java to MariaDB and MySQL databases. Prior to 2.7.14, 3.3.5, 3.4.3, and 3.5.9, the connector encodes and decodes protocol text and performs client-side escaping under the assumption that the connection character set is UTF-8. The server can report a mid-session change to character_set_client through OK-packet session-state tracking, including a change caused by SET NAMES, a stored routine or trigger, server configuration, or a hostile server. If character_set_client changes to a non-UTF-8 value, the driver continues to read and write UTF-8 while the server interprets the same bytes under another encoding, causing silent data corruption and a client/server charset-confusion mismatch that can defeat byte-wise quoting or escaping. The fix accepts only utf8, utf8mb3, or utf8mb4 after initialization; any other value causes SQLException with SQLState 08000 and closes the connection. This issue is fixed in versions 2.7.14, 3.3.5, 3.4.3, and 3.5.9.

Published

Date2026-08-28

Updated

Date2026-08-28

RISK INFORMATION (Score: 5.9)

cvss3

Base Score: 5.9

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:H/A:N

Impact Score

3.6

Exploitability

2.2

REFERENCES

CVE-2026-55857

SUMMARY

MariaDB Connector/J is used to connect applications developed in Java to MariaDB and MySQL databases. Prior to 2.7.14, 3.3.5, 3.4.3, and 3.5.9, PAM dialog authentication can be coerced into transmitting the account password over an insecure connection. The mysql_clear_password plugin is gated behind a secure transport, but the sibling PAM handler SendPamAuthPacketFactory, named dialog by the server, does not declare that requirement and inherits the default secure-required value false; older branches implement the same affected behavior in SendPamAuthPacket. A hostile or man-in-the-middle server can send an Authentication Switch Request for dialog over plain TCP, causing the driver to return the user's password in cleartext when sslMode=DISABLE and restrictedAuth=null, which is the default configuration. Properly verified TLS and local Unix sockets are not exposed to this transport vector. This issue is fixed in versions 2.7.14, 3.3.5, 3.4.3, and 3.5.9.

Published

Date2026-08-28

Updated

Date2026-08-28

RISK INFORMATION (Score: 5.9)

cvss3

Base Score: 5.9

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:H/I:N/A:N

Impact Score

3.6

Exploitability

2.2

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…